Benicar
Daiichi settles undisclosed drug side-effects case for $300 million
August 2, 2017Research and Development, Sales and Marketing Benicar, Daiichi Sankyo, biotech, drugs, pharma, pharmaceutical
Daiichi Sankyo has settled a case alleging that it did not fully disclose adverse side-effects of its drug, Benicar, with …
Daiichi Sankyo cuts 16% of US staff
March 27, 2015Sales and Marketing Benicar, Daiichi Sankyo, FDA, Ranbaxy, Welchol, ambit, colesevelam, cuts, olmesartan
Daiichi Sankyo is laying off 16% of its staff at its US commercial headquarters as the company braces itself for …
Daiichi-Sankyo pays $39m to settle allegations
January 12, 2015Sales and Marketing Azor, Benicar, Daiichi Sankyo, Daiichi-Sankyo, Tribenzor, Welchol, kickbacks, us justice
Daiichi-Sankyo will pay the US government and state Medicaid programmes $39 million to resolve claims that it violated the False …
Latest content
Global coalition calls for stronger government action on COPD
September 18, 2026
Global health researchers call for more equitable partnerships
September 17, 2026
Liverpool launches £20m lab for infectious disease drug discovery
September 16, 2026
Circle Health Group expands into UK laboratory operations
September 15, 2026
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
September 14, 2026
